Introduction
Over the last 30 years, there has been increasing recognition of the role that autoantibodies play in neurological disorders. These mainly act on ligand-gated ion channels (receptors) and voltage-gated ion channels. This has led to an emerging family of autoimmune channelopathies that can be diagnosed by simple laboratory tests and, in the main, respond well to immunotherapies that reduce the levels of the pathogenic autoantibodies. Many of these channels are mutated in genetic disorders, but these conditions, of course, are not associated with autoantibodies and do not respond to immunological treatments.
This review will start with a few words about the immune system and how it can be involved in the pathophysiology of neurological disease. The immune system consists broadly of primary lymphoid organs (thymus, bone marrow), secondary lymphoid organs (lymph nodes and spleen), and lymphocytes and antigen-presenting cells, some of which circulate in the blood and/or are found patrolling or sessile in nonlymphoid organs of the body. The macrophages, dendritic cells, and other antigen-presenting cells present short peptide sequences (epitopes) derived from foreign antigens to specific T cells (with the peptide within a grove on the surface of a human leukocyte antigen (HLA) molecule so that it can interact with the highly specific T cell receptor). The T cells become activated and are able to direct the immune response against the cells that express the HLA-epitope sequence, or to direct the synthesis of antibodies (immunoglobulins, first IgM and then IgG) against other epitopes on the antigen. The immunoglobulin genes are able to undergo rearrangement and somatic mutation leading to maturation of the B cell response and persistence of those that make the highestaffinity antibodies. Although the main role of the immune system is to protect against infection, this can have unfortunate consequences if the immune response crossreacts with target antigens in the host, or if the expression of microbial antigens within cells leads to T cell-or macrophage-mediated damage. This is particularly the case when the immune response initiates an inflammatory infiltration in the antigen-expressing tissue, and if the antibodies activate the serum complement components that lead to cell lysis.
Immune diseases of the nervous system include those that are associated with infections, such as HTLV-1-associated encephalopathy and HIV-AIDS-associated encephalitis, and those in which an inflammatory response against the brain is caused by unknown mechanisms, such as multiple sclerosis. In each of these conditions the balance between cellular (T cell)-and humoral (antibody)-mediated mechanisms is not always clear and may vary between individual patients.
Autoantibodies in Neurological Diseases
Neurological diseases associated principally with autoantibodies to various antigenic targets can be divided broadly into two groups: those in which the antibodies are markers for an inflammatory process and those in which the antibodies are directly pathogenic. This distinction is important for the clinicians, since the latter diseases are, in general, easier to treat. Autoantibodies are traditionally measured by indirect immunohistochemistry on the target tissue, followed by western blotting, identification of the target antigen by molecular techniques, and development of an ELISA or other laboratory test for measuring antibodies to the defined antigen. This approach has been very fruitful for the study of the autoantibodies that are found in a proportion of patients with paraneoplastic neurological disorders. These conditions are defined as those in which the neurological disease is secondary to the presence of a tumor but is not directly caused by the tumor itself. They result from the immune response that is generated against the tumor, which can usually be shown to express the neuronal antigen; the resulting T cells and autoantibodies crossreact with neuronal tissue. The autoantibodies indicate that the patient has a tumor, but they are not usually directly pathogenic, as the antigenic target is often intracellular (but see voltage-gated calcium channels, below). The neurological disorder in these patients is thought to be caused by a T cell-mediated attack on the neurons expressing the antigen, and the associated inflammation that this produces (Bataller and Dalmau, 2004) .
By contrast, autoantibodies to ion channels and other functional membrane proteins may not be detected by immunohistochemistry and usually do not bind well on western blots of denatured tissue, but are measured with high specificity and sensitivity by immunoprecipitation of the native protein extracted from appropriate tissue by gentle detergent and tagged with radioactively labeled neurotoxins, or of the protein expressed by recombinant technology in mammalian cell lines, purified and tagged directly with 125 I or 35 S. In addition, recent advances include binding of serum antibodies to the surface of mammalian cell lines expressing cloned channels.
Autoimmune Channelopathies at the Neuromuscular Junction
The neuromuscular junction (NMJ) serves as a prototype synapse with well-defined pre-and postsynaptic components that express ion channels with well-described identity (Figure 1 ). Diseases that interfere with function at the NMJ lead to muscle weakness or muscle hyperactivity (Table 1) . They can be caused by neurotoxic poisoning (e.g., botulism, snake bite) but in the western world the most common cause is autoimmunity, and the prototypic disease is myasthenia gravis (MG). Here we will first briefly discuss current understanding of the role of autoimmunity in MG, and then how this has led to recognition of new antibody-mediated channelopathies in the peripheral, autonomic, and central nervous systems. For a detailed review of MG, see Drachman (1994) .
Myasthenia Gravis
MG usually presents after puberty, and patients first presenting in older age (>50 years) are increasingly recognized. It is a chronic disease, and spontaneous remissions are infrequent. The patient complains of muscle weakness and fatigue that may first affect the ocular muscles with diplopia (double vision) and ptosis (drooping of the eyelids). However, individual patients can have very different patterns and severity of weakness. Weakness may remain in the ocular muscles (ocular MG) or spread to the facial, bulbar, and respiratory muscles (bulbar MG) or also involve the limbs (generalized MG). Choking and respiratory failure can be life threatening. The weakness classically gets worse with repetition and improves with rest or with use of acetycholinesterase inhibitors (which increase the amount of ACh in the synaptic cleft at the neuromuscular junction).
The account of how myasthenia gravis became recognized as an autoimmune disease is told elsewhere (Vincent, 2002) . The most crucial events were the active immunization of rabbits against acetylcholine receptors (AChRs) purified from the electroplax of electric eel, which induced muscle weakness and paralysis. This was phenotypically similar to MG and shown to be due principally to antibodies that crossreacted with the rabbit's muscle AChR and reduced the number of functional AChRs (Patrick and Lindstrom, 1973) . This model of MG, experimental autoimmune MG (EAMG), has been reproduced in many other species and consistently involves an antibody-mediated mechanism with no direct contribution from T cell immunity, as shown by transfer of disease to normal animals by injection of serum or IgG antibodies. Contemporaneously, it was shown that the number of AChRs was reduced at the NMJs of MG patients using radioactively labeled a-bungarotoxin (Fambrough et al., 1973; Ito et al., 1978) . Antibodies to human AChR were present in patients with MG (Lindstrom et al., 1976) , these antibodies could passively transfer disease to mice (Toyka et al., 1975) , and removal of the IgG antibodies from MG patients by plasma exchange led to marked clinical improvement . Thymic Pathology and Disease Heterogeneity MG is associated with thymic pathology. Young adult patients (<50 years), usually female, frequently have an enlarged thymus that contains germinal centers very similar to those normally restricted to lymph nodes and spleen. These younger patients often carry the HLA antigen haplotype B8DR3 (Compston et al., 1980) . In the medulla, close to the germinal centers, there are muscle-like ''myoid'' cells that express AChR , and epithelial cells of the thymic cortex express individual AChR subunits (e.g., Salmon et al., 1998) (Roxanis et al., 2002) and produce AChR antibodies (Scadding et al., 1981) , and serum AChR antibody levels decline to some extent after removal of the thymus. These surprising findings probably reflect the fact that many autoantigens, or epitopes of them, are normally expressed in thymic medulla cells where they should lead to deletion of those T cells that might become reactive against self-antigens, but in MG this process fails and the T cells become activated instead. Older patients, however, are more frequently male and are not associated with this HLA antigen, and their thymuses are normally involuted.
In addition, about 10% of MG patients have a thymic tumor. These tumors are associated not only with MG but also with other neurological diseases (see below). The patients always have AChR antibodies but also often have antibodies to interferon-a and interleukin-12 (Shiono et al., 2003; Yoshikawa et al., 2006) . More detailed discussions of the role of the thymus in MG can be found elsewhere (Marx et al., 1997) .
Mechanisms of AChR Loss
Autoantibodies to AChRs are found in the majority of MG patients, very infrequently in healthy individuals or other diseases, and are thought to be directly pathogenic. The AChR is a pentameric membrane protein. AChR antibodies are high affinity, mainly IgG1 subclass, react variably with AChR extracted from muscles of other species and, most importantly, bind mainly to extracellular epitopes of the native AChR, which are available to circulating antibodies . Because these epitopes are conformation dependent, the antibodies bind poorly to denatured AChR, to recombinant subunits, or to the peptide sequences. Their specificity for different sequences of the AChR subunits therefore has been derived by competition experiments with monoclonal antibodies raised against purified AChR or against recombinant subunits (Tzartos et al., 1981) . A variable proportion bind to a region on each of the two AChR a subunits called the main immunogenic region, which includes aa 64-76 (Tzartos et al., 1988 , but some bind to other epitopes on the a subunits or on the other subunits (Whiting et al., 1986) .
The weakness in MG is caused by loss of the AChRs at the neuromuscular junction, probably compounded by morphological damage to the motor endplate. This means that the postsynaptic depolarization (endplate potential) resulting from each nerve impulse is too small to achieve the critical firing threshold required for opening of sufficient voltage-gated sodium channels to initiate an action potential in the muscle fiber. As a result, the safety factor for transmission is compromised. The mechanisms by which the antibodies lead to loss of AChRs was investigated in detail in the late 70s and early 80s. Although the MG sera often reduced the binding of 125 I-a-bungarotoxin to AChR in solution or to mouse muscle cell lines in culture (Drachman et al., 1982) , there are relatively few studies that show that the antibodies can reduce AChR function at the neuromuscular junction (Weinberg and Hall, 1979; Burges et al., 1990) . A reversible block of function can be achieved by some MG IgG preparations applied to AChR-expressing cells in vitro, which may lead over time to a more persistent block, but it is not clear how important this is to muscle in vivo (Jahn et al., 2000; Figure 2) .
A more important mechanism proposed was increased turnover of the AChR. The MG antibodies reduced the number of surface AChRs in cell lines in a temperatureand time-dependent manner (e.g., Heinemann et al., 1977) , and this effect could be prevented by cleaving the antibodies into monovalent Fab fragments . These and many other studies indicated that cross-linking of the AChRs by divalent IgG and subsequent internalization and degradation of the AChRs was a major mechanism, at least in vitro, and was independent of serum complement factors. To prove that this could also occur in vivo, passive transfer experiments were performed by injecting the MG IgG antibodies and measuring the turnover of the AChRs in vivo (Stanley and Drachman, 1978; Wilson et al., 1983a) . A third mechanism is complement activation by the IgG1 and IgG3 antibodies (these subclasses are strong complement activators) with lysis of the postsynaptic membrane and morphological damage (Engel et al., 1977; Sahashi et al., 1978 Sahashi et al., , 1980 . Complement-dependent lysis is likely to be an important mechanism, since the damage will not only reduce the number of AChRs and the available membrane for insertion of new AChRs, but also affect the number and distribution of the voltage-gated sodium channels that are concentrated at the bottoms of the postsynaptic folds (Figure 1 ). This would lead to further difficulties in achieving the postsynaptic depolarization required to initiate the muscle action potential, as demonstrated in both MG biopsies and EAMG muscle (Ruff and Lennon, 1998) . In the EAMG model, complement inhibitors protect against disease (Piddlesden et al., 1996) , and muscles deficient in complement regulators may be more susceptible (Kaminski et al., 2004) . The evidence for each of the three mechanisms is summarized in Table 2 . Compensatory Mechanisms and Phenotypic Variability Like most biological systems, the NMJ tries to limit the physiological defect resulting from disease mechanisms. First, an increase in gene expression for the AChR subunits and synthesis rates of AChRs (Wilson et al., 1983b) indicates postsynaptic compensatory mechanisms in the human disease, and also in the animal model (Asher et al., 1993) . Second, an increase in quantal release from the motor nerve terminal, correlating with the reduced amplitude of the miniature endplate potentials , suggested retrograde signaling from the postsynaptic muscle to the presynaptic nerve terminal. However, the time course of these changes in individual endplates is unknown, and the mechanisms are largely unexplored. In chronically a-bungarotoxin-treated rats, used as a model of MG, the quantal content became sensitive to inhibitors of CaM KII and some tyrosine kinases, suggesting that the expression of these, or their ability to affect the quantal content, was altered (Plomp and Molenaar, 1996) . Since nNOS is anchored postsynaptically at the neuromuscular junction (Kusner and Kaminski, 1996) , NO is a potential retrograde signal.
Within an individual, AChR antibody levels correlate with disease severity during treatments , but antibody levels between patients are highly variable and do not correlate well with severity. This raises the possibility that individual differences in the specificity of the antibodies, or the existence of antibodies to other NMJ antigens, might also play a role. In addition, the compensatory changes mentioned above might differ between individual's muscles and help to explain the considerable variability in severity and distribution of muscle weakness that is common in MG. Another factor, recently recognized in experimental MG models, is a possible role of rapsyn (Hoedemaekers et al., 1998) . This cytoplasmic protein is essential for the clustering of AChRs under the presynaptic motor nerve terminal ( Figure 1 ) and appears to help stabilize the AChRs during autoimmune attack (Losen et al., 2005) . Different expression levels of rapsyn, and ability of the muscle to upregulate its expression (or that of Block was reversible by washing during the first few minutes but increasingly became irreversible over 60 min. Recordings were made from outside-out patches with single pulses of 1 mM acetylcholine (ACh) applied at 0.25 Hz before, during, and after incubation periods of 50, 120, 600, and 1800 s with the IgG (see horizontal bars). Taken with permission from Jahn et al. (2000) . The AChR exists in a fetal and adult form ( Figure 3 ) differing only in the presence of the g (fetal) or 3 (adult) subunit. Fetal AChR is expressed during development and in humans is replaced by adult AChR in the last weeks of intrauterine life (contrasting with mice, where replacement is not complete until around postnatal day 15). Fetal AChR is upregulated in denervated muscle and is expressed at low levels in adult human muscle (MacLennan et al., 1997) and at some NMJs in the multiply innervated extraocular muscle fibers (Kaminski, 1998) , and also in the myoid cells of the thymus (see above). Indeed, antibodies that compete with monoclonal antibodies specific for fetal AChR (Whiting et al., 1986) are not uncommon in MG patients, and in some instances, these antibodies do directly inhibit ACh-induced currents or reduce miniature endplate potentials (Weinberg and Hall, 1979) probably by binding to a site on the g subunit overlapping the ACh-binding site. Many female patients with MG develop the disease before pregnancy, and one could predict that these antibodies would be harmful to the developing fetus. A transient form of MG occurring in the neonate and due to transfer of maternal antibodies is well recognized. Arthrogryposis multiplex congenital (multiple bent joints) can be caused by any condition that limits fetal movement in utero. It can be associated with other life-threatening deformities (e.g., lung hypoplasia). A few cases of arthrogryposis were identified in which there were maternal antibodies specific for fetal AChR. In some of these cases, the mother did not have any evidence of MG herself but suffered recurrent fetal loss, stillbirths, or early termination because of ultrasound evidence of severe deformities in utero (reviewed by Polizzi et al., 2000) . The maternal antibodies inhibited ACh-induced currents ( Figure 3) and Na + ion fluxes through fetal but not through adult AChRs (Riemersma et al., 1996) , and passive transfer of maternal antibodies to pregnant mice resulted in a high proportion of paralyzed and deformed offspring (Figure 3 ; Jacobson et al., 1999) . These cases are rare, representing about 1.5% of cases of arthrogryposis (Dalton et al., 2006) , but highlight the possibility that this and other developmental or neurodevelopmental disorders (e.g., autism; Dalton et al., 2003) might be caused by maternal antibodies. There are a few other instances in which maternal antibodies are thought to be responsible for fetal deformities (e.g., Rothenberg et al., 2004) . MG without AChR Antibodies About 15% of MG patients do not have AChR antibodies, yet these patients respond to immunotherapies, and their serum or plasma antibodies can transfer a defect in neuromuscular transmission to mice, indicating that they also have an antibody-mediated condition (Mossman et al., 1986) . Subsequent studies suggested that a serum IgG (Bufler et al., 1998) or non-IgG component, possibly IgM, reduced ACh-induced Na + ion flux or ACh-induced currents (Yamamoto et al., 1991; BarrettJolley et al., 1994; Plested et al., 2002) , and it was proposed that these putative antibodies might act via an indirect second messenger pathway that was associated with increased AChR desensitization in the presence of agonist. A possible target could be a NMJ specific receptor that acted as a receptor for tyrosine or other kinases. MuSK (muscle-specific kinase), which is a NMJ-specific receptor tyrosine kinase (Valenzuela et al., 1995) , was a possible candidate. MuSK is essential during development of the NMJ when it orchestrates the agrin-induced clustering of fetal AChRs under the developing motor nerve terminal (Sanes and Lichtman, 1999) . Antibodies to MuSK were found in up to 70% of MG patients without AChR antibodies (Hoch et al., 2001; Scuderi et al., 2002) ; the antibodies bound to MuSK expressed in intact cell lines and were able to inhibit agrin-induced clustering in C2C12 cell lines. Interestingly, the MuSK antibody-positive sera also partially stimulated agrin-independent clustering, perhaps because they bind divalently to MuSK, leading to its dimerization and activation.
MuSK antibodies were found to be IgG, not IgM, and their presence did not correlate with that of the AChR inhibitor activity of the sera (Plested et al., 2002) , so they do not explain the putative IgM-mediated increased desensitization of the AChR described above. MuSK antibodies are found in only a proportion of patients without AChR antibodies and extremely infrequently in those with AChR antibodies, suggesting that they define a distinct form of MG. The patients often have severe bulbar dysfunction that can be difficult to treat effectively with immunosuppression. The reasons for this are not clear, but muscle atrophy of facial and tongue muscles is common (Farrugia et al., 2006) , and it is possible that MuSK antibodies induce muscle atrophy, particularly in certain muscles. Preliminary findings using C2C12 mouse myotube cultures suggest that MuSK antibodies can upregulate MuRF-1, a muscle atrophy-related gene product (Glass, 2003) , and that MuRF-1 is upregulated in mouse masseter muscle after passive transfer with MuSK antibodies (Benveniste et al., 2005) .
It is still not clear how MuSK antibodies cause MG. The NMJs in biopsies from MuSK patients do not show loss of AChR or complement deposition (Shiraishi et al., 2005) , reflecting the fact that the antibodies are mainly in the IgG4 subclass (McConville et al., 2004) , which does not activate complement. There have been few electrophysiological studies on patients' muscles, and in one the miniature endplate potentials were reduced despite a normal number of AChRs (Selcen et al., 2004) . This is analogous to findings in mouse muscle after passive transfer of patients' sera (Mossman et al., 1986; Burges et al., 1994) and suggests that the antibodies may affect function directly, perhaps by alteration of MuSK-dependent downstream signaling events. Interestingly, a new MuSK-interacting protein, called Dok-7, has recently been discovered (Okada et al., 2006) . Mutations in the DOK7 gene are found in patients with a genetic form of limb-girdle myasthenia in which the NMJs are small but with relatively normal levels of AChRs Slater et al., 2006) . Some of the clinical features in these patients resemble somewhat those of the MuSK antibody patients, tentatively suggesting that loss of downstream signaling from MuSK may be a common mechanism. There have been two reports of animal models induced by immunization against MuSK (Shigemoto et al., 2006; Jha et al., 2006) , but the mechanisms at the NMJ are not yet clearly defined.
The patients without either AChR or MuSK antibodies remain an enigma. However, based on the possibility that the putative IgM antibodies might bind directly, but with low affinity, to the AChR, and the fact that similar electrophysiological findings occurred with binding of a monoclonal antibody C7 to the AChR delta subunit (Spreadbury et al., 2005) , we have began to look for lowaffinity AChR antibodies in MG sera. Some of the previously AChR antibody-negative patients have antibodies that bind to cell lines expressing high concentrations of AChR on their surface but do not bind to the AChR in solution (M. Leite, J. Cossins, D. Beeson, N. Willcox, and A.V., unpublished data).
Lambert Eaton Myasthenic Syndrome-A VoltageGated Calcium Channelopathy
The findings in myasthenia were crucial in leading the way to identification of further autoimmune channelopathies and provided clinical and experimental criteria that helped to define them (Table 3 ). The Lambert Eaton myasthenic syndrome (LEMS) is another disorder in which muscle weakness is the predominant symptom but differs from MG in that the weakness is more common in the trunk and limbs, less frequently affects the facial muscles, and may improve rather than worsen with repetitive activity (Eaton and Lambert, 1957) . Many of the patients have autonomic symptoms, and about half have a small cell lung cancer (O'Neill et al., 1988) .
Seminal investigations in the 1950s and 1960s showed that the defect was presynaptic, with marked reductions in the quantal content (number of ACh packets released per nerve impulse) and that the ACh release increased with high-frequency nerve stimulation or by raising extracellular calcium (Lambert and Elmqvist, 1971; Elmqvist and Lambert, 1968) . These observations suggested that a reduction in the influx of calcium into the motor nerve terminal might underlie the disease mechanism. Later freeze-fracture studies showed that the active zone particles on the presynaptic membrane, generally considered to be the voltage-gated calcium channels (VGCC), were reduced in numbers and formed into small aggregates rather than into the normal double parallel arrays (Fukunaga et al., 1983) . The crucial evidence that the disease was autoimmune followed the demonstration that the majority of patients responded well to immunomodulatory therapy and that the disease could be passively transferred to mice. Injection of IgG (daily for 3 or more days) transferred the electrophysiological features of the disease, reduced quantal content and increased sensitivity to extracellular calcium , and changes in the number and distribution of active zone particles (Fukuoka et al., 1987a (Fukuoka et al., , 1987b Engel et al., 1989) . These observations clearly implicated VGCCs as a target antigen in the disease.
VGCCs are a family of multimeric ion channels with different biophysical and pharmacological properties. The a1 subunit comprises the main calcium pore and determines the functional subtype (P/Q, N, L, R, or T) and sensitivity to various neurotoxins. Therefore, it was possible to use specific neurotoxins that label subtypes of the VGCC, to demonstrate antibodies in patients with LEMS (using the same general approach as that employed for AChR antibodies in MG). Antibodies were first detected in 40%-50% of patients using 125 I-conotoxin GVIA ( 125 I-CgTx) from Conus geographus (Sher et al., 1989) to label N-type VGCCs extracted in digitonin from a human neuronal cell line. However, antibodies that bind to the N-type VGCC (encoded by the a1B) are not thought to be functionally effective, and some at least bind to intracellular determinants, including the b subunit (Verschuuren et al., 1998) . Subsequently, using 125 I-conotoxin MVIIC ( 125 I-CmTx) from C. magus, antibodies to mammalian P/Q-type VGCC antibodies were demonstrated in >85% of LEMS patients (Motomura et al., 1995; Lennon et al., 1995) . The P/Q-type VGCC antibodies are present in patients with or without small cell lung cancer (SCLC). SCLC cells express functionally active VGCC on their surface, and Ca 2+ influx through these channels is inhibited by incubation in IgG from LEMS patients (Roberts et al., 1985) . Presumably, therefore, the body's immune response to the tumor leads to antibodies directed at these VGCCs, which then crossreact with those at the NMJ to cause the neurological disease. Thus, SCLC-associated LEMS is a condition in which antibodies secondary to the presence of a tumor are causative, rather than merely a marker for the associated tumor. However, VGCC antibodies can also be found at low levels in some patients with lung cancer without peripheral neurological dysfunction, including SCLC-associated cerebellar ataxia (Graus et al., 2002) . In these cases, the antibodies are probably acting as markers for the presence of the tumor rather than playing a pathogenic role, since the patients do not generally improve with immunosuppressive therapies. The cause of LEMS in the patients without cancer is not clear.
There have been few experiments to dissect the antigenic epitopes of VGCC antibodies. An antigenic site located on an extracellular region (domain III in the S5-S6 linker) of the a1A subunit of the P/Q-type VGCC is recognized by 50% of LEMS patients (Takamori et al., 2000) , but it is not clear what proportion of patients' antibodies bind to this epitope and whether these antibodies are particularly pathogenic. Some patients' sera also bind to synaptotagmin (Takamori et al., 1995) , and immunization against VGCC and synaptotagmin peptides has induced some of the electrophysiological changes of LEMS (Takamori et al., 1994) .
Mechanisms of VGCC Loss and Compensatory Mechanisms
The antibodies reduce K + -stimulated Ca 2+ influx in cell lines (Roberts et al., 1985) , but these effects take hours to develop and are dependent on cross-linking by divalent antibody and independent of complement (Peers et al., 1990 ; see Table 2 ). The specificity of the antibodies for different VGCCs and their in vitro functional effects were studied using HEK cells expressing individual VGCC subtypes (Pinto et al., 1998 (Pinto et al., , 2002 . IgG from all LEMS patients tested bound to the a1A (P/Q-type) cell line, and overnight incubation in LEMS IgG caused a dose-dependent reduction in the K + -stimulated Ca 2+ influx into the a1A but not the a1B, a1C, a1D, or a1E cell lines. Only 2/6 LEMS sera bound to the a1B (Ntype) VGCC, but neither of these patients' sera reduced the whole-cell calcium currents in these cells. Similarly, overnight incubation in LEMS antibodies reduced the P-type component of voltage-dependent currents in cultured rat Purkinje cells, and P-and Q-type currents in cultured rat granule cells, without affecting N-type VGCC currents. A concomitant upregulation in residual (R-type) VGCC current was observed in both of these cultured cells (Figure 4) . These results strongly suggest that LEMS IgG binds to multiple subtypes of VGCC but only functionally downregulates the P/Q subtype and 
(2002). (C-F) The effect of control and LEMS IgG on the whole-cell calcium currents in cultured Purkinje cells (after 13 days culture in vitro). Representative time courses and traces from control IgG-treated Purkinje cells (C and D) and LEMS IgG-treated Purkinje cells (E and F) exposed to u-Aga
IVA, u-CgTx GVIA, and nifedipine are shown. Pretreatment with LEMS IgG causes a marked reduction in the u-Aga IVA-sensitive calcium current. Taken with permission from Pinto et al. (1998). that there are compensatory increases in the expression of other subtypes. Recently, Buchwald et al. (2005) , using a ''macro-patch clamp'' technique, demonstrated a reduction in quantal release from the motor nerve terminal during incubation in LEMS Ig, implying that there may be a more direct blocking effect in some patients.
The compensatory changes seen in cultured cerebellar cells are also likely to be important in vivo. In mice passively transferred with LEMS IgG over 9 days, there was not only a decrease in the quantal content, but also a corresponding increase in the sensitivity of transmitter release to the L-, N-, and R-type VGCC (Giovannini et al., 2002) . Whether these channels are present under normal conditions and unmasked, or whether they are newly synthesized during the passive transfer process, has not been determined (Giovannini et al., 2002) . Moreover, do they replace the P-type channels in the active zones, which seems unlikely from the LEMS freeze-fracture studies, or are they expressed elsewhere on the presynaptic nerve terminal?
One of the striking features of LEMS is the autonomic dysfunction that can be disabling. Patients frequently have dry mouth, constipation, erectile impotence, and urinary problems. While it was initially thought that Ntype VGCCs were most important in controlling the release of ACh at the autonomic synapses (Lundy and Frew, 1993) , P/Q-and/or R-type VGCCs are also involved, and the precise combination of VGCC subtypes appears to vary according to the neurotransmitter, tissue, and species (Waterman, 2000) . In the passive transfer model, all LEMS IgG tested was capable of downregulating P/Q-type VGCC, and again the downregulation of the P/Q-VGCC was mirrored by an upregulation in other channels (R-and to a lesser degree N-type) (Waterman et al., 1997) .
It is interesting to compare the effects of the antibodies with those of genetic ablation in the VGCC. a1A subunit-deficient mice (a 1A 2/2 ) died 4 weeks postnatal, after developing a rapidly progressive ataxia and dystonia (Jun et al., 1999) . P-and Q-type currents in Purkinje and cerebellar granule cells were absent in the a 1A 2/2 mice, whereas the L-and N-type VGCC channels were elevated in Purkinje cells. Moreover, transmission in hippocampal slices was spared in these mice, the lack of P/Q channels being at least partially compensated for by a rise in N and R channels (Jun et al., 1999) . Similar findings were shown at the NMJs (Urbano et al., 2003) . Thus, compensatory changes occur in both autoimmune and genetic channelopathies.
a3 Ganglionic AChR Antibodies in Autoimmune Autonomic Neuropathies A subgroup of patients with autonomic disturbance have a monophasic illness that develops over days or weeks, persists for some months, and then may partially recover. The symptoms can affect both the sympathetic and parasympathetic systems with orthostatic hypotension, impaired sweating, dry mouth and eyes, sexual dysfunction, urinary retention, impaired pupillary responses, and defects in control of heart rate. There may also be gastrointestinal disturbance such as constipation or diarrhea.
Vernino and colleagues hypothesized that there might be antibodies to the ganglionic form of AChR and were able to demonstrate these in a proportion of patients (Vernino et al., 2000) using radioactively labeled epibatidine to tag the a3-and b4-containing form of nicotinic AChR, which is present at ganglionic synapses of the autonomic system. Mice lacking the a3 subunit lack autonomic ganglia and have severe autonomic dysfunction with prominent mydriasis (Xu et al., 1999) . Evidence for the pathogenicity of these antibodies is now strong. The titer correlates with the degree of autonomic impairment not only within an individual patient but also between patients (in which respect it contrasts with AChR antibodies in MG). Active immunization has led to a convincing animal model of the disease (Lennon et al., 2003) , and a single injection of the rabbit or human antibodies into mice leads to autonomic dysfunction, which lasts for a few days and, interestingly, is followed by a compensatory overshoot in function as the mice recover .
Voltage-Gated Potassium Channelopathies
Acquired Neuromyotonia A spectrum of diseases is associated with muscle hyperactivity or stiffness. Some are genetic (see Kleopa and Barchi, 2002) whereas others are autoimmune. The disorders that arise from peripheral nerve hyperexcitability include neuromyotonia and cramp-fasciculation syndrome (Hart et al., 2002) . Acquired neuromyotonia typically presents with muscle fasciculations and cramps, stiffness, myokymia, pseudomyotonia (delayed relaxation of contracted muscles), and hyperhydrosis (increased sweating). The limb and trunk muscles are most commonly affected. Up to 20% of patients also have sensory symptoms such as paraesthesias, suggesting that sensory as well as motor nerves may be hyperexcitable (Lance et al., 1979) .
Electrophysiologically, the patients' muscles show spontaneous and repetitive (doublet, multiplet) discharges of single motor units with variably high intraburst frequency. This neuromyotonic activity has been blocked in every case by local curare and variably by nerve block (Isaacs and Heffron, 1974; Newsom-Davis and Mills, 1993) , indicating that it originates in the motor nerve rather than in the muscle itself. Recent electrophysiological studies provide evidence that the most distal portion of the nerve close to the NMJ is where hyperexcitability usually develops (Arimura et al., 2005; Maddison et al., 2006) . Cramp-fasciculation syndrome is probably a milder version of the same condition, and the distinction from neuromyotonia lies in their electromyographic and clinical features: neuromyotonic discharges are not detected in the cramp-fasciculation syndrome (Hart et al., 2002) .
Like MG, NMT can be associated with other autoimmune diseases, including MG, rheumatoid disease, systemic lupus erythematosus, diabetes mellitus, and others (Newsom-Davis and Mills, 1993) . Acquired NMT can also be a paraneoplastic syndrome, associated with thymoma in 10%-20% of cases, and more rarely with small cell lung carcinoma, Hodgkin's lymphoma, and other malignancies. NMT patients improve with plasma exchange and other immunosuppressive treatments, and passive transfer of IgG antibodies to mice resulted in resistance to curare (Sinha et al., 1991) , a modest increase in quantal content and prolonged action potentials in sensory nerves (Shillito et al., 1995) . One IgG preparation tested caused repetitive activity in dorsal root ganglion cultures. Overall, the results were very similar to those obtained with low concentrations (50 mM) of the potassium channel blockers 3,4-diamino pyridine or 4-amino-pyridine. Immunoprecipitation of 125 I-dendrotoxin-VGKCs extracted from human or rabbit cortex demonstrated antibodies to VGKCs in about 40% of patients, although the antibody levels are not very high, and the test is less robust than that for AChRs or VGCCs (Shillito et al., 1995) . Dendrotoxin only binds to the Kv1.1, 1.2, and 1.6 members of the Shaker-type potassium channels. Immunostaining of Xenopus oocytes expressing individual VGKC subunits proved more sensitive and showed that most patients did have antibodies to one or the other of these channels (Hart et al., 1997) . This has recently been extended by binding of patient sera to relevant neural tissues with high expression of VGKC, as well as to different Kv subunits expressed on the surface of transfected mammalian cells, reaching a higher sensitivity of detecting VGKC antibodies (Kleopa et al., 2006) .
VGKCs constitute one of the most ubiquitous and diverse group of ion channels found in the body (Jan and Jan, 1997) . Functional Kv channels are formed by homotetramers or heterotetramers of a subunits (Catterall, 1988) . The tetramer of K + channel a subunits is often associated with an auxiliary b subunit, which can modify the gating properties of the heteromultimeric channel complex (MacKinnon, 1991) . Heteromeric K + channels of different subunit stoichiometry may be localized to different subcellular compartments, presumably because their channel properties are better suited for the physiological requirements of those locations. Kva subunits are glycoproteins with six transmembrane segments. The S4 segment of each monomer serves as the voltage sensor. The voltage-dependent inactivation process involves conformational changes in the amino terminus of any one of the four subunits (Doyle et al., 1998) .
How autoantibodies impair VGKC function remains unclear, but, as in the case of other antibodies to ion channel proteins, they likely target extracellular epitopes of the a subunit. This would explain why sera from patients bind poorly to denatured Kv subunits in western blots (Kleopa et al., 2006) . The human VGKC antibodies bind to recombinant a subunits expressed as tetramers at the cell membrane of transfected cells, but not to intracellularly retained immature subunit proteins (Kleopa et al., 2006) . This may be due to the fact that they recognize posttranslational modifications such as N-glycosylation, or tertiary structure that depends on subunit interactions (Shi et al., 1996; Manganas and Trimmer, 2000) . At least in our studies so far, we could not detect any reactivity of NMT sera to the Kvb subunit.
VGKC antibodies are heterogeneous and may bind to multiple Kv subunits (Hart et al., 1997; Kleopa et al., 2006) . Although in most cases the autoantibodies belong to the IgG subclass, in rare occasions IgM VGKC antibodies have been detected and had similar suppressing effects on potassium channel currents (Kurono et al., 2006) . VGKC antibodies in NMT do not appear to block the function of Shaker-type K + channels directly, since short incubation (up to 2 hr) of cultured neuronal cell lines with IgG from NMT patients had no effect.
However, when applied for several hours, they reduce K + channel current amplitudes without changing gating kinetics (Sonoda et al., 1996; Nagado et al., 1999; Figure 5) . Thus, antibodies in sera from NMT patients appear, in a mechanism independent of added complement, to accelerate channel turnover and degradation of VGKC through crosslinking of the channels by divalent antibodies (Tomimitsu et al., 2004 ). Morvan's Syndrome In 1890, Morvan described ten patients with symptoms of neuromyotonia, one of whom had severe insomnia and mental confusion (see Serratrice and Azulay, 1994) . This was first termed Morvan's fibrillary chorea because of the marked muscle fibrillations and myoclonic movements, but it is usually now called Morvan's syndrome. Reportedly extremely rare, it can be associated with heavy metal intoxication (gold, mercury), other toxins, and also thymomas, hinting at an autoimmune etiology. Over the last 10 years, about ten patients have been reported in the English literature, of whom around half had high titers of VGKC antibodies. Clinically, the patients present with a combination of peripheral hyperexcitability with autonomic and CNS disturbance, but the relative contributions of these can differ (Lee et al., 1998; Barber et al., 2000) . VGKC antibodies can be modestly or highly raised and in general patients either improve spontaneously over time or respond more quickly to immunosuppressive treatments, particularly plasma exchange (Halbach et al., 1987; Madrid et al., 1996; Heidenreich and Vincent, 1998; Lee et al., 1998; Liguori et al., 2001) or immunoadsorption . The recognition that the CNS symptoms as well as the more peripheral symptoms improved with this treatment drew attention to the potential roles of serum autoantibodies to ion channels in other CNS diseases. Limbic Encephalitis An autoimmune, nonparaneoplastic VGKC antibodymediated disease affecting exclusively the CNS and most prominently the limbic areas has recently been recognized (Buckley et al., 2001; Vincent et al., 2004; Thieben et al., 2004) . The most striking examples are patients who develop, acutely or subacutely, memory loss and confusion, leading over days or weeks to epileptic seizures (either temporal lobe or partial complex seizures). Cognitive impairment is profound with substantial retrograde and anterograde memory loss. On magnetic resonance imagine (MRI) there is high signal in the hippocampal regions(s) ( Figure 5 ). This is usually termed limbic encephalitis (LE) and previously has been thought of as a paraneoplastic neurological condition with poor prognosis, due to the presence of an associated tumor, and poor response to treatments. In contrast to the paraneoplastic form, VGKC antibody-associated LE cases do not usually have a tumor and can respond well, albeit sometimes over weeks rather than days, to immunotherapies Thieben et al., 2004) , with good recovery of memory and other CNS functions. Interestingly, some of the patients have evidence for rapid eye movement sleep behavioral disorder (Iranzo et al., 2006) , indicating a relationship with Morvan's syndrome in whom sleep disorder is prominent. However, in contrast to patients with Morvan's syndrome, LE patients lack clinical manifestations of peripheral nerve hyperexcitability, and most have normal peripheral electrophysiological studies as well . VGKC Antibodies in Neuromyotonia, Morvan's Syndrome, and Limbic Encephalitis Although VGKC antibody levels differ broadly between the three syndromes, these alone are unlikely to provide an explanation for the different clinical expression of the diseases. In particular, the highest antibodies are found in patients with LE, but these patients seldom have any evidence of neuromyotonia. Morvan's syndrome falls between the other two in having intermediate levels of VGKC antibodies and a broader range of symptoms, but this does not explain why sleep disorder can be so marked in these patients. As an aside, in each of these conditions there are patients with typical features who do not have detectable VGKC antibodies, indicating that other antibodies may play a similar role.
Kv channels are expressed widely in the central and peripheral nervous systems but show a highly specific localization of individual Kv1 subunits in each area that may be functionally important. Kv1.1 and Kv1.2 are coexpressed at the juxtaparanodal regions of the axons surrounding the nodes of Ranvier (Wang et al., 1993; Arroyo and Scherer, 2000) (Figure 5 ). Here, they account for the K i current that can be recorded by patch clamping of myelinated axons (Safronov et al., 1993; Reid et al., 1999) and contribute to the regulation of axonal membrane excitability, preventing repetitive discharges. Additional voltage-gated K + conductances have been recorded in mammalian axons, including the slowly activating current, K s (Roper and Schwarz, 1989; Safronov et al., 1993) , ascribed to KCNQ2 expressed at the nodes (Devaux et al., 2004) , and the fast nodal current, K f2 , which may be generated by Kv3.1b (Corrette et al., 1991; Devaux et al., 2003) . While there is no specific labeling with a control serum (Fa), the serum from a patient with MoS (Fb) binds to the same areas colocalizing with Kv1.2. In the hippocampal CA3 area (Fc), Kv1.1 is strongly expressed in the mossy fiber layer (mf) and much less in the stratum pyramidale (py), radiatum (rd), and oriens (or). The serum from a patient with LE strongly labels the mf layer colocalizing with Kv1.1. In CA1 (Fd), Kv1.1 is strongly expressed in the rd and less in the or layers, and the LE serum binds to the same areas colocalizing with Kv1.1. Merged images are shown in the right column, including nuclear staining (blue) to demonstrate the different layers. Scale bars, 10 mm in Fa and Fb, 50 mm in Fc and Fd. Adapted with permission from Kleopa et al. (2006). In the CNS, a more complex distribution of numerous VGKC subunits in different regions has emerged (Veh et al., 1995) , but the cerebellum and hippocampus have received most attention due to the genetic disorders associated with dysfunction of VGKC in these areas, especially epilepsy and episodic ataxia (Browne et al., 1994; Eunson et al., 2000) . Kv1.1-1.6 are highly expressed in different combinations in the cerebellar molecular and granule cell layers as well as at the basket cell terminals (Chung et al., 2001) , and in specific layers of the hippocampus that contain excitatory axon terminals, most prominently in the molecular layer of the dentate gyrus, in the CA3 mossy fiber zone, and in the stratum radiatum of CA1-3 (Sheng et al., 1994; Wang et al., 1994; Monaghan et al., 2001) (Figure 5 ). K + channels play a major role in regulating the excitability of hippocampal neurons by modulating neurotransmitter release, postsynaptic responses to excitatory inputs, neuronal spike properties, and firing frequency (Johnston et al., 2000) .
This complex expression pattern of Kv channels in the CNS and PNS gives rise to the question of whether the contrasting clinical phenotypes of NMT, Morvan's syndrome, or LE, each associated with antibodies to dendrotoxin-binding VGKC, could be explained by differences in their subunit specificity. Double immunohistochemistry on different regions of the nervous system, comparing the binding of commercial antibodies to individual Kv1 subunits with that of sera from patients with NMT, Morvan's syndrome, or LE, showed that almost all patients had Kv1.2 antibodies that could bind to the juxtaparanodes and to regions in the CNS with high Kv1.2 expression; a few only had Kv1.6 antibodies that bound in the CNS, but only LE sera labeled the hippocampal areas that are enriched in excitatory, Kv1.1-positive axon terminals (Kleopa et al., 2006; Figure 5 ). These results were confirmed by quantitative binding of sera to the respective subunits expressed in transfected cells, with Kv1.1-binding rates of 19.7%-38% for LE, as opposed to 0%-2.67% for NMT sera (Kleopa et al., 2006 ). An insufficient number of Morvans' syndrome sera were investigated to draw conclusions regarding their specificity, although Kv1.6 antibodies were predominant in one patient Kleopa et al., 2006) . Although these studies have provided a possible explanation for the different clinical pictures, many questions remain. In particular, why the hippocampus should be so vulnerable in limbic encephalitis (in Morvan's syndrome there is seldom MRI evidence of inflammatory changes in the hippocampus, and memory loss is less evident) and whether the MRI findings indicate prior breakdown of the blood-brain barrier or antibody-mediated inflammatory changes in the hippocampus. Furthermore, in most sera, regardless of the associated phenotype, reactivity to more than one Kv subunit type can be detected, indicating that patients may have a mixture of individual antibodies that have specific activity to different subunits, or individual antibodies that crossreact with multiple subunits (Hart et al., 1997; Kleopa et al., 2006) . Further factors, such as the accessibility of different peripheral or central neural tissues to circulating Kv1 antibodies, as well as the repertoire of Kv1 channels expressed in each area with partially overlapping function, may also determine the threshold for developing neuronal dysfunction.
Further investigation of autoimmune VGKC disorders will require animal models, which are currently being developed. Immunization against isolated Kv subunits may indicate which particular roles individual subunits and the respective autoantibodies play in different areas of the nervous system but will require techniques to ensure that the blood-brain barrier or the peripheral nerve septate-like paranodal junctions are made ''leaky'' in order to allow the antibodies to gain access, and will not explain why they do so in the patients. Furthermore, more than one Kv subunit may have to be compromised in each area in order to produce a phenotype, since animal models in which the juxtaparanodal concentration of Kv1.1 and Kv1.2 is impaired, including mice deficient in the juxtaparanodal adhesion molecules TAG-1 (Poliak et al., 2003; Traka et al., 2003) or Caspr2 (Poliak et al., 2003) show no hyperexcitability of peripheral nerves. On the other hand, Kv1.1 null mice develop spontaneous seizures with hippocampal excitability (Smart et al., 1998) , underscoring the crucial role of this subunit alone.
Other Channelopathies
Autoimmune channelopathies are expanding and clinically important (e.g., see Buckley and Vincent, 2005 ). Rasmussen's encephalitis is a severe form of intractable childhood epilepsy that is usually restricted to one hemisphere and leads to marked cognitive decline. The disease is associated with inflammatory and degenerative changes in the cerebral cortex and is extremely resistant to treatment. Hemispherectomy may be the only way of preventing seizure activity and helping to protect the child against increasing cognitive problems. Antibodies to glutamate receptor 3 (GluR3) were first detected in Rasmussen's encephalitis following the serendipitous observation that immunization of rabbits with the GluR3 extracellular domain resulted in inflammation of the cortex and seizure activity (Rogers et al., 1994) . The mechanisms by which these antibodies might cause seizures and cortical damage are several (reviewed in detail by McNamara et al., 1999) , and immunization against GluR3 in rats confirms their potential pathogenicity (Levite and Hermelin, 1999) , but the frequency of these antibodies in patients is more controversial (Watson et al., 2004) , and they may not be specific for Rasmussen's encephalitis (Mantegazza et al., 2002) . Moreover, there is accumulating evidence that Rasmussen's encephalitis is a T cell-mediated disorder (Bien et al., 2005) , and it may be that the GluR3 antibodies are secondary to the neuronal damage evoked by frequent prolonged seizures rather than causing it (although plasma exchange was strikingly effective in some patients [e.g., Rogers et al., 1994] ).
Another target of potential interest is the NMDA receptor. A portion of the patients with systemic lupus erythematosus develop neuropsychiatric disorders with varying degrees of headache, learning difficulties, seizures, or psychosis. This condition is associated with serum antibodies to DNA, ribosomal, and phospholipid antigens, but none of these antibodies have been confirmed as pathogenic toward the CNS. However, a recent study found that anti-DNA antibodies crossreact with the NR2A and NR2B subunits of the NMDA receptor through a conserved pentapeptide sequence (DeGiorgio et al., 2001 ). The crossreacting antibodies were shown to cause hippocampal cell death when injected into mouse brains, and animals immunized with the NR2A peptide developed high titers of specific NR2A antibodies, which were able to gain access to the hippocampus (but only when they were given intraperitoneal lipopolysaccharide, which is thought to open the blood-brain barrier). These animals performed less well in water maze and T maze tasks (Kowal et al., 2004) . The antibodies may act by stimulation of the NMDA receptor, leading to glutamate-induced neurotoxicity.
Finally, an intriguing new channelopathy has emerged among patients with an inflammatory neurological disease, thought to be similar to multiple sclerosis. Over 60% of patients with neuromyelitis optica, but very few of those with multiple sclerosis, have serum antibodies that bind to the pia, microvessels, choroid plexus, and Virchow-Robbin spaces on brain tissue sections. The target of these antibodies has now been defined as aquaporin-4, one of the water channels (Lennon et al., 2005) . Aquaporin-4 is located in the astrocytic endfeet, and its distribution is determined by agrin-mediated interactions with the cell membrane. Whether these antibodies are directly pathogenic and how they act in vivo is not yet determined.
Conclusions
Autoimmune channelopathies have come a long way since autoantibodies to AChR were first shown in the 1970s and now extend to the autonomic and central nervous systems. They offer interesting parallels to the genetic disorders that involve mutations in the same channels (Table 1 ), but they are usually adult-onset disorders, some of which present relatively acutely, and some of which may improve spontaneously. In most cases the underlying cause of the disease is not clear, but a tumor (thymoma or small cell lung cancer) must always be considered. The antibodies act mainly by increasing the turnover of the target antigen, and by complementmediated damage in MG; direct block of function by antibodies binding to the agonist site or ion channel pore is more variable. In each of these conditions, clinical data demonstrate wide heterogeneity of disease expression, and experimental data strongly suggest that there are compensatory changes that might help to explain some of this phenotypic variation. These changes may also, of course, occur in the genetic channelopathies, and understanding the mechanisms by which they happen in vivo may point the way to therapeutic possibilities.
